Developing and delivering mRNA lipid nanoparticle therapeutics
Örn Almarsson is the Co-Founder and CEO of a startup biopharma company called Axelyf (Hafnarfjörður, Iceland & MA, USA) that is developing lipid technologies to safely and efficiently deliver mRNA therapeutics. Örn previously worked for companies like Merck (PA, USA) and Moderna (MA, USA), where he and his team developed therapeutic delivery systems for mRNA, before co-founding Axelyf. At ELRIG Research & Innovation (10–11 March 2025; London, UK), Örn spoke about mRNA lipid nanoparticle technology for delivering therapeutics in the future. In his talk, he demonstrated that there are ways to deliver therapeutics that produce large proteins like antibodies from...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
